Ruxolitinib
Reading tools
Approved by the FDA on 4 December 2014, Jakafi is used for Polycythemia Vera when response to hydroxyurea, which reduces blood cells, is inadequate. Polycythemia Vera is a stem cell disease caused by excessive production of erythrocytes (red blood cells) in the bone marrow.
Jakafi acts by blocking JAK1 and JAK2 (Janus kinase), molecules involved in blood cell production and immune responses. Its most common side effects, such as anemia and headache, resemble those of most cancer drugs.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.